Search Existing Tissue Requests

The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.


Search Terms:


Investigator: G. William Rebeck

Project Title: APOE ISOFORM-SPECIFIC GLYCOSYLATION IN ALZHEIMER�S DISEASE

Date: December 21, 2021 at 5:02 pm

Request ID: T1611

Aim 1: identify glycosylated forms of APOE in human plasma

Aim 2: determine whether plasma glyco-APOE species differ by APOE genotype

Aim 3: determine whether plasma glyco-APOE species are altered in Alzheimer’s disease

Aim 4:


Investigator: Allen D. Roses, MD

Project Title: TOMM40-‘523 haplotype relationship to age of onset of dementia

Date: December 21, 2021 at 5:02 pm

Request ID: T1612

Aim 1: Compare the TOMM40-‘523 genotype calls previously obtained with Sanger Sequencing Assay Results

Aim 2: Analyze the interaction between APOE and TOMM40 genotypes and ae of onset of symptomatic Alzheimer’s Disease

Aim 3:

Aim 4:


Investigator: J. Randall Slemmon Ph.D.

Project Title: Tau Fragment CSF Biosignature in AD

Date: December 21, 2021 at 5:02 pm

Request ID: T1613

Aim 1: Determine if the pTau fragment profile changes in CSF during the course of AD.

Aim 2: Determine if the totalTau fragment profile (mid-mid region) changes in CSF during the course of AD.

Aim 3:

Aim 4:


Investigator: A Fagan

Project Title: Prospective Measures of Outcome in Rapidly Progressive Dementia

Date: December 21, 2021 at 5:02 pm

Request ID: T1614

Aim 1: Determine clinically-measurable variables that differentiate between patients with various forms of RPD

Aim 2: Quantify neuroinflammation, neurodegeneration, and synaptic dysfunction in patients with RPD utilizing cerebrospinal fluid measures

Aim 3: Evaluate associations between biomarkers (Aim 2) and clinical outcomes (including cognitive performance) measured in individuals with RPD

Aim 4:


Investigator: Eric McDade, DO

Project Title: DIAN Expanded Registry: Exploratory Genetic Counseling and Testing (GCT) Program

Date: December 21, 2021 at 5:02 pm

Request ID: T1615

Aim 1: Identify families that carry autosomal dominant mutations on PS1, PS2, APP

Aim 2: Identify novel genes that cause Alzheimer’s disease

Aim 3:

Aim 4:


Investigator: Dr Raffaele Ferrari

Project Title: Genomics studies of Frontotemporal Dementia

Date: December 21, 2021 at 5:02 pm

Request ID: T1617

Aim 1: Generate genotyping data for cases diagnosed with frontotemporal dementia

Aim 2: Perform association and rare variants analyses for novel disease-associated loci and genes discovery

Aim 3: Provide back raw genotyping data once generated

Aim 4: Possibly use DNA for validating results using Sanger or next generation sequencing techniques


Investigator: Sumit Sarkar

Project Title: Study of vascular dysfunction in brain of two transgenic rodent models of Alzheimer�s disease (AD): dietary impact and relevance to human AD

Date: December 21, 2021 at 5:02 pm

Request ID: T1616

Aim 1: Determine the contribution of neurovascular units (endothelial cells, astrocytes, pericytes, microglia, and basement membranes) and associated cerebrovascular integrity in the deposition of microvascular and/or parenchymal amyloid beta (A�) and/or abnormal tau protein in two rodent models of AD

Aim 2: Attempt to accelerate AD pathology through high fat diet-induced obesity in the AD Tg rat and Tg-SwDI (cerebral amyloid angiopathy; CAA) mouse models of AD

Aim 3: Correlate findings from specific aims 1 and 2 with human brain tissue to further explore whether Aß and/or hyperphosphorylated-tau (p-tau) contribute to endothelial dysfunction, increase BBB permeability and lead to neuronal degeneration

Aim 4:


Investigator: Beth Stevens

Project Title: of Microglia and Complement in Synapse Loss in Alzheimer�s Disease

Date: December 21, 2021 at 5:02 pm

Request ID: T1715

Aim 1: Examine synapse-associated complement proteins in human AD tissue

Aim 2: Examine synaptic proteins inside microglia in human AD tissue

Aim 3:

Aim 4:


Investigator: Eric A. Schon

Project Title: Diagnosis of AD based on perturbed MAM function in blood and CSF

Date: December 21, 2021 at 5:02 pm

Request ID: T1716

Aim 1: To test the hypothesis that AD can be diagnosed in blood (e.g. whole blood, fractionated blood components, plasma, and serum) and/or CSF based on the analysis of phenotypes associated with increased ER-mitochondrial communication

Aim 2:

Aim 3:

Aim 4:


Investigator: John Kauwe

Project Title: Cell free single stranded DNA concentration in CSF as biomarker to diagnose Alzheimer�s disease status

Date: December 21, 2021 at 5:02 pm

Request ID: T1717

Aim 1: Determine the association between cell free single stranded DNA concentration in CSF and Alzheimer�s disease status

Aim 2: Establish if cell free single stranded DNA in CSF can be use as biomarker to diagnose Alzheimer�s disease.

Aim 3: Observe any variability between non-demented CSF serum and Alzheimer�s case CSF serum such as number of cell count, and nucleonic material.

Aim 4: